Main Baseline Characteristics of the 185 Randomized Patients, According to Treatment Group
| . | Early HDT Group (n = 91) . | Late HDT Group (n = 94) . |
|---|---|---|
| Age (yr) | 48 ± 5 | 47 ± 5 |
| Male gender | 39 (43) | 42 (45) |
| Durie-Salmon stage | ||
| I-150 | 3 (3) | 2 (2) |
| II | 9 (10) | 15 (16) |
| III | 79 (87) | 76 (82) |
| M component (MIg) | ||
| IgG | 50 (55) | 39 (41) |
| IgA-151 | 13 (14) | 34 (36) |
| IgM | 1 (1) | 0 |
| IgD | 3 (3) | 5 (5) |
| BJ protein only-151 | 21 (23) | 13 (14) |
| None | 3 (3) | 3 (3) |
| Hemoglobin (g/L) | 107 ± 22 | 107 ± 21 |
| ≤100 g/L | 30 (33) | 36 (38) |
| Serum calcium (mmol/L) | 2.5 ± 0.4 | 2.6 ± 0.7 |
| >2.6 mmol/L | 22 (24) | 20 (21) |
| Serum albumin (g/L) | 39.6 ± 6.6 | 39.0 ± 6.3 |
| Serum creatinine (μmol/L) | 112 ± 58 | 128 ± 117 |
| >150 μmol/L | 14 (15) | 15 (16) |
| BM plasmocytosis (%) | 36 ± 23 | 34 ± 24 |
| Serum β2microglobulin (mg/L) | 3.8 ± 2.9 | 3.7 ± 2.4 |
| ≥3 mg/L | 41 (46) | 46 (51) |
| CRP (mg/L)-152 | 7.0 ± 12.1 | 8.2 ± 14.1 |
| >6 mg/L | 11 (22) | 16 (27) |
| . | Early HDT Group (n = 91) . | Late HDT Group (n = 94) . |
|---|---|---|
| Age (yr) | 48 ± 5 | 47 ± 5 |
| Male gender | 39 (43) | 42 (45) |
| Durie-Salmon stage | ||
| I-150 | 3 (3) | 2 (2) |
| II | 9 (10) | 15 (16) |
| III | 79 (87) | 76 (82) |
| M component (MIg) | ||
| IgG | 50 (55) | 39 (41) |
| IgA-151 | 13 (14) | 34 (36) |
| IgM | 1 (1) | 0 |
| IgD | 3 (3) | 5 (5) |
| BJ protein only-151 | 21 (23) | 13 (14) |
| None | 3 (3) | 3 (3) |
| Hemoglobin (g/L) | 107 ± 22 | 107 ± 21 |
| ≤100 g/L | 30 (33) | 36 (38) |
| Serum calcium (mmol/L) | 2.5 ± 0.4 | 2.6 ± 0.7 |
| >2.6 mmol/L | 22 (24) | 20 (21) |
| Serum albumin (g/L) | 39.6 ± 6.6 | 39.0 ± 6.3 |
| Serum creatinine (μmol/L) | 112 ± 58 | 128 ± 117 |
| >150 μmol/L | 14 (15) | 15 (16) |
| BM plasmocytosis (%) | 36 ± 23 | 34 ± 24 |
| Serum β2microglobulin (mg/L) | 3.8 ± 2.9 | 3.7 ± 2.4 |
| ≥3 mg/L | 41 (46) | 46 (51) |
| CRP (mg/L)-152 | 7.0 ± 12.1 | 8.2 ± 14.1 |
| >6 mg/L | 11 (22) | 16 (27) |
Mean values (±SD) are given for continuous variables, while numbers of patients (percentages) are given otherwise.
All progressive, ie, >25% increase in MIg level confirmed by at least 3 consecutive measurements 2 months apart.
P value = .22 and .13 by the Fisher’s exact two-sided test, for MIgA and BJ, respectively.
Based on 108 assessed patients, 49 in the early HDT group and 59 in the late group.